BREAKING: FDA Pharmacy Compounding Advisory Committee (PCAC) Narrowly Votes 8-6 With 1 Abstention on Thursday July 23, 2026 to Recommend Adding BPC-157 to the Section 503A Bulks List; the First PCAC Recommendation to Add a Popular Research Peptide to the Compounding Pathway, Overriding FDA Career-Staff Briefing Documents That Recommended Against Inclusion; Committee's Advisory Vote Is Non-Binding and Typically Followed by FDA; Formal Rulemaking to Implement Would Take Six to Eighteen Months
The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List, in a win for HHS Secretary Robert F. Kennedy Jr.'s peptide deregulation agenda. The narrow vote overrode FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides under review, citing immunogenicity concerns, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use. The vote sequencing during the Thursday session followed extensive public comment; Hims Chief Medical Officer Dr. Anant Vinjamoori argued during his testimony that a no vote would push peptides deeper into an unregulated gray market rather than end the underlying demand. PCAC recommendations are advisory and non-binding; the FDA typically follows them, and formal rulemaking to implement the recommendation would take approximately 6 to 18 months. Panel composition is a significant contextual factor: before the meeting, more than a half-dozen new members with documented ties to the peptide industry were added to the PCAC.